Search

Your search keyword '"Viteri, S."' showing total 485 results
Start Over Author "Viteri, S."
485 results on '"Viteri, S."'

1. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

Author

Zemanová, M., Besse, B., Bonnet, C., Cadranel, J., Chouaid, C., Cortot, A., Debieuvre, D., Delclaux, B., Denis, F., Duchemann, B., El Kouri, C., Ferrand, F.R., Ginoux, M., Hilgers, W., Madroszyk, A., Masson, P., Mazieres, J., Molinier, O., Moro-Sibilot, D., Pichon, E., Mascaux, C., Robinet, G., Roch, B., Zalcman, G., Schmidtke-Schrezenmeier, G., Schuette, W., Urban, L., Gottfried, M., Nechushtan, H., Peled, N., Wollner, M., Zer, A., Baldini, E., Bonanno, L., Bonetti, A., Cappuzzo, F., Delmonte, A., Galetta, D., Maio, M., Minotti, V., Rea, A., Romano, G., Tassinari, D., Tonini, G., Dziadziuszko, R., Karaszewska, B., Szczęsna, A., Cobo, M., De Castro, J., Felip, E., Garcia Campelo, M.R., Hernández, A., Moran, T., Provencio, M., Viteri, S., Dasgupta, A., Gabrail, N., Giaccone, G., Harshad, A., Liu, S., Oubre, D., Panikkar, R., Razaq, M., Sanborn, R., Garcia Campelo, R., Remon, J., Costantini, D., and Vasseur, B.

Published
2023
Full Text
View/download PDF

3. OA21.06 ctDNA Dynamics, Prognostic Markers and Resistance Mechanisms in Tepotinib-Treated METex14 Skipping NSCLC in the VISION Trial

Author

Le, X., primary, Garassino, M.C., additional, Ahn, M.-J., additional, Felip, E., additional, Cortot, A.B., additional, Sakai, H., additional, Mazieres, J., additional, Thomas, M., additional, Viteri, S., additional, Conte, P., additional, Yang, J.C.-H., additional, Iams, W.T., additional, Griesinger, F., additional, Stroh, C., additional, Juraeva, D., additional, Wang, D., additional, Johne, A., additional, and Paik, P.K., additional

Published
2023
Full Text
View/download PDF

4. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

Author

Besse, B., primary, Felip, E., additional, Garcia Campelo, R., additional, Cobo, M., additional, Mascaux, C., additional, Madroszyk, A., additional, Cappuzzo, F., additional, Hilgers, W., additional, Romano, G., additional, Denis, F., additional, Viteri, S., additional, Debieuvre, D., additional, Galetta, D., additional, Baldini, E., additional, Razaq, M., additional, Robinet, G., additional, Maio, M., additional, Delmonte, A., additional, Roch, B., additional, Masson, P., additional, Schuette, W., additional, Zer, A., additional, Remon, J., additional, Costantini, D., additional, Vasseur, B., additional, Dziadziuszko, R., additional, Giaccone, G., additional, Zemanová, M., additional, Besse, B., additional, Bonnet, C., additional, Cadranel, J., additional, Chouaid, C., additional, Cortot, A., additional, Delclaux, B., additional, Duchemann, B., additional, El Kouri, C., additional, Ferrand, F.R., additional, Ginoux, M., additional, Mazieres, J., additional, Molinier, O., additional, Moro-Sibilot, D., additional, Pichon, E., additional, Zalcman, G., additional, Schmidtke-Schrezenmeier, G., additional, Urban, L., additional, Gottfried, M., additional, Nechushtan, H., additional, Peled, N., additional, Wollner, M., additional, Bonanno, L., additional, Bonetti, A., additional, Minotti, V., additional, Rea, A., additional, Tassinari, D., additional, Tonini, G., additional, Karaszewska, B., additional, Szczęsna, A., additional, De Castro, J., additional, Garcia Campelo, M.R., additional, Hernández, A., additional, Moran, T., additional, Provencio, M., additional, Dasgupta, A., additional, Gabrail, N., additional, Harshad, A., additional, Liu, S., additional, Oubre, D., additional, Panikkar, R., additional, and Sanborn, R., additional

Published
2023
Full Text
View/download PDF

5. Response to crizotinib in a non-small-cell lung cancer patient harboring an EML4-ALK fusion with an atypical LTBP1 insertion

Author

Aguado C, Gil MDLL, Yeste Z, Giménez-Capitán A, Teixidó C, Karachaliou N, Viteri S, Rosell R, and Molina-Vila MA

Subjects
Lung cancer, NSCLC, EML4-ALK, LTBP1, crizotinib, targeted therapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Cristina Aguado,1,* Maria-de-los-Llanos Gil,2,* Zaira Yeste,1 Ana Giménez-Capitán,1 Cristina Teixidó,1 Niki Karachaliou,2 Santiago Viteri,2 Rafael Rosell,1,2 Miguel A Molina-Vila1 1Laboratory of Oncology, Pangaea Oncology, 2Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain *These authors contributed equally to this work Abstract: Fusion of the anaplastic lymphoma receptor tyrosine kinase gene (ALK) with the echinoderm microtubule-associated protein 4 gene (EML4) is the second most common actionable alteration in non-small-cell lung cancer, with a frequency of 5%. Here, we present a case of an EML4-ALK-positive patient with an atypical in-frame insertion from the LTBP1 gene in the canonical junction of variant 1. The patient was a 39-year-old never-smoker female diagnosed with Stage IV lung adenocarcinoma. A core biopsy was negative for EGFR and KRAS mutations but positive for ALK immunohistochemistry and fluorescence in situ hybridization. When submitted to nCounter, the sample showed a 3'/5' imbalance indicative of an ALK rearrangement, but failed to give a positive signal for any of the variants tested. Finally, a band with a molecular weight higher than expected appeared after reverse transcriptase-polymerase chain reaction analysis. When Sanger sequencing was performed, the band revealed an atypical EML4-ALK fusion gene with an in-frame 129 bp insertion. A 115 bp segment of the insertion corresponded to an intronic region of LTBP1, a gene located in the short arm of chromosome 2, between ALK and EML4. The patient received crizotinib and showed a good therapeutic response that is still ongoing after 12 months. Our result suggests that short in-frame insertions of other genes in the EML4-ALK junction do not affect the sensitivity of the EML4-ALK fusion protein to crizotinib. Keywords: lung cancer, NSCLC, EML4-ALK, LTBP1, crizotinib, targeted therapy

Published
2018

6. PPD02.03 Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Analysis of All Patients From VISION Cohorts A and C

Author

Garassino, M.C., primary, Thomas, M., additional, Felip, E., additional, Sakai, H., additional, Le, X., additional, Veillon, R., additional, Smit, E.F., additional, Mazieres, J., additional, Cortot, A.B., additional, Raskin, J., additional, Viteri, S., additional, Chih-Hsin Yang, J., additional, Ahn, M.-J., additional, Wu, Y.-L., additional, Ma, R., additional, Zhao, J., additional, O'Brate, A., additional, Berghoff, K., additional, Bruns, R., additional, Otto, G., additional, and Paik, P., additional

Published
2023
Full Text
View/download PDF

7. OA01.08 Clinical Response to Tepotinib According to Circulating Tumor (ct)DNA Biomarkers in Patients with Advanced/Metastatic NSCLC with High-level MET Amplification (METamp) Detected by Liquid Biopsy (LBx)

Author

Le, X., primary, Paz-Ares, L.G., additional, Van Meerbeeck, J., additional, Viteri, S., additional, Cabrera-Galvez, C., additional, Baz, D.V., additional, Kim, Y.-C., additional, Kang, J.-H., additional, Stroh, C., additional, Juraeva, D., additional, Bruns, R., additional, Otto, G., additional, Johne, A., additional, and Paik, P.K., additional

Published
2023
Full Text
View/download PDF

8. CO73 Amivantamab Versus Real-World Clinical Practice in Europe and the US for Patients With Advanced Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Author

Chouaid, C, primary, Girard, N, additional, Kron, A, additional, Scheffler, M, additional, Knott, C, additional, Bosquet, L, additional, Trigo, J, additional, Viteri, S, additional, Sebastian, M, additional, Popat, S, additional, Rahhali, N, additional, Toueg, R, additional, Rodrigues, B, additional, Diels, J, additional, Schioppa, CA, additional, Cabrieto, J, additional, Sermon, J, additional, Perualila, NJ, additional, Erdmann, N, additional, Mielke, J, additional, Nematian-Samani, M, additional, Pfaira, I, additional, Martin-Fernandez, C, additional, Mahadevia, P, additional, Li, T, additional, Pick-Lauer, C, additional, Adamczyk, A, additional, Penton, J, additional, and Wolf, J, additional

Published
2022
Full Text
View/download PDF

9. Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies

Author

Moran, T., Wei, J., Cobo, M., Qian, X., Domine, M., Zou, Z., Bover, I., Wang, L., Provencio, M., Yu, L., Chaib, I., You, C., Massuti, B., Song, Y., Vergnenegre, A., Lu, H., Lopez-Vivanco, G., Hu, W., Robinet, G., Yan, J., Insa, A., Xu, X., Majem, M., Chen, X., de las Peñas, R., Karachaliou, N., Sala, M.A., Wu, Q., Isla, D., Zhou, Y., Baize, N., Zhang, F., Garde, J., Germonpre, P., Rauh, S., ALHusaini, H., Sanchez-Ronco, M., Drozdowskyj, A., Sanchez, J.J., Camps, C., Liu, B., Rosell, R., Colinet, B., De Grève, J., Germonpré, P., Chen, H., Du, J., Gao, Y., Hu, J., Kong, W., Li, L., Li, R., Li, X., Liu, J., Ren, W., Wen, L., Xiao, X., Yang, J., Yang, M., Yang, Y., Yin, J., Yue, X., Zhang, J., Zhu, L., Bombaron, P., Chouaid, C., Dansin, E., Fournel, P., Fraboulet, G., Gervais, R., Hominal, S., Kahlout, S., Lecaer, H., Lena, H., LeTreut, J., Locher, C., Molinier, O., Monnet, I., Oliviero, G., Schoot, R., Thomas, P., Vergnènegre, A., Berchem, G., Al Husaini, H., Aparisi, F., Arriola, E., Ballesteros, I., Barneto, I., Bernabé, R., Blasco, A., Bosch-Barrera, J., Calvo de Juan, V., Carcereny, E., Catot, S., De las Peñas, R., Dómine, M., Felip, E., García-Campelo, M.R., García-Girón, C., García-Gómez, R., Garcia-Sevila, R., Gasco, A., Gil, J., González-Larriba, J.L., Hernando-Polo, S., Jantus, E., Jiménez, B., Lianes, P., López-López, R., López-Martín, A., López-Vivanco, G., Macias, J.A., Marti-Ciriquian, J.L., Montoyo, R., Morales-Espinosa, D., Morán, T., Moreno, M.A., Pallares, C., Parera, M., Pérez-Carrión, R., Porta, R., Reguart, N., Rosillo, F., Sanchez, J.M., Sullivan, I., Terrasa, J., Trigo, J.M., Valdivia, J., Viñolas, N., Viteri, S., Botia-Castillo, M., Mate, J.L., Perez-Cano, M., Ramirez, J.L., Sanchez-Rodriguez, B., Taron, M., Tierno-Garcia, M., Mijangos, E., Ocaña, J., Pereira, E., Shao, J., Sun, X., and O'Brate, R.

Published
2014
Full Text
View/download PDF

10. Targeting PD-1/PD-L1 in lung cancer: current perspectives

Author

González-Cao M, Karachaliou N, Viteri S, Morales-Espinosa D, Teixidó C, Sánchez Ruiz J, Molina-Vila MÁ, Santarpia M, and Rosell R

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

María González-Cao,1 Niki Karachaliou,1 Santiago Viteri,1 Daniela Morales-Espinosa,1 Cristina Teixidó,2 Jesús Sánchez Ruiz,3 Miquel Ángel Molina-Vila,2 Mariacarmela Santarpia,4 Rafael Rosell1,2,5,61Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain; 2Pangaea Biotech SL, Barcelona, Spain; 3Centro Nacional de Investigación Oncología (CNIO), Madrid, Spain; 4Medical Oncology Unit, Human Pathology Department, University of Messina, Messina, Italy; 5Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain; 6Fundación Molecular Oncology Research, Barcelona, SpainAbstract: Increased understanding of tumor immunology has led to the development of effective immunotherapy treatments. One of the most important advances in this field has been due to pharmacological design of antibodies against immune checkpoint inhibitors. Anti-PD-1/PD-L1 antibodies are currently in advanced phases of clinical development for several tumors, including lung cancer. Results from Phase I–III trials with anti-PD-1/PD-L1 antibodies in non-small-cell lung cancer have demonstrated response rates of around 20% (range, 16%–50%). More importantly, responses are long-lasting (median duration of response, 18 months) and fast (50% of responses are detected at time of first tumor evaluation) with very low grade 3–4 toxicity (less than 5%). Recently, the anti-PD-1 antibody pembrolizumab received US Food and Drug Administration (FDA) breakthrough therapy designation for treatment of non-small-cell lung cancer, supported by data from a Phase Ib trial. Another anti-PD-1 antibody, nivolumab, has also been approved for lung cancer based on survival advantage demonstrated in recently released data from a Phase III trial in squamous cell lung cancer.Keywords: immunotherapy, immunoncology, cancer, checkpoint inhibitors

Published
2015

11. EP08.02-081 Cabozantinib Plus Atezolizumab in First or Second-Line Advanced NSCLC and Previously-Treated EGFR Mutant Advanced NSCLC

Author

Neal, J.W., primary, Lim, F.L., additional, Aix, S.P., additional, Viteri, S., additional, Santoro, A., additional, Spencer, K., additional, Fang, B., additional, Khrizman, P., additional, Kim, J., additional, Subbiah, V., additional, Sudhagoni, R., additional, Samaraweera, L., additional, Andrianova, L., additional, and Felip, E., additional

Published
2022
Full Text
View/download PDF

12. OA03.05 Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Primary Analysis of the Confirmatory VISION Cohort C

Author

Thomas, M., primary, Garassino, M., additional, Felip, E., additional, Sakai, H., additional, Le, X., additional, Veillon, R., additional, Smit, E., additional, Mazieres, J., additional, Cortot, A., additional, Raskin, J., additional, Viteri, S., additional, Yang, J.C.-H., additional, Ahn, M.-J., additional, Wu, Y.-L., additional, Ma, R., additional, Zhao, J., additional, O'Brate, A., additional, Berghoff, K., additional, Bruns, R., additional, Otto, G., additional, and Paik, P., additional

Published
2022
Full Text
View/download PDF

13. EP16.02-007 Detection of Clinically Relevant Fusions and Exon Skipping Alterations in Non Small Cell Lung Cancer Patients Liquid Biopsies

Author

Sánchez-Herrero, E., primary, Giménez-Capitán, A., additional, Robado de Lope, L., additional, Serna-Blasco, R., additional, Viteri, S., additional, Sanz-Moreno, S., additional, Mayo-de-Las-Casas, C., additional, Calvo, V., additional, Rosell, R., additional, González-Rumayor, V., additional, Provencio, M., additional, Romero, A., additional, and Molina, M.Á., additional

Published
2022
Full Text
View/download PDF

14. 19P Stable disease (SD) on amivantamab in post-platinum epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutated non-small cell lung cancer (NSCLC): A response-based analysis

Author

Girard, N., primary, Park, K., additional, Viteri, S., additional, Schioppa, C.A., additional, Diels, J., additional, Oguz, M., additional, Rodrigues, B.H., additional, Rahhali, N., additional, Sermon, J., additional, Ghilotti, F., additional, Li, T., additional, Knoblauch, R.E., additional, Mahadevia, P., additional, and Cho, B.C., additional

Published
2022
Full Text
View/download PDF

15. 157MO Immune gene signatures for predicting pathological response of NSCLC patients treated with neoadjuvant chemoimmunotherapy

Author

Casarrubios, M., primary, Cruz-Bermudez, A., additional, Sierra-Rodero, B., additional, Nadal, E., additional, Insa Molla, M.A., additional, Garcia Campelo, M.R., additional, Garcia Benito, C., additional, Domine Gomez, M., additional, Majem Tarruella, M., additional, Rodriguez-Abreu, D., additional, Martinez, A., additional, De Castro Carpeno, J., additional, Cobo Dols, M., additional, Lopez Vivanco, G., additional, Vinolas Segarra, N., additional, Barneto Aranda, I.C., additional, Viteri, S., additional, Massuti Sureda, B., additional, and Provencio Pulla, M., additional

Published
2022
Full Text
View/download PDF

16. 20P Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC)

Author

Trigo, J., primary, Cho, B.C., additional, Park, K., additional, Girard, N., additional, Viteri, S., additional, Garrido, P., additional, Krebs, M.G., additional, Thayu, M., additional, Knoblauch, R.E., additional, Xie, J., additional, Bauml, J.M., additional, Schnepp, R.W., additional, Londhe, A., additional, Mahadevia, P., additional, and Leighl, N., additional

Published
2022
Full Text
View/download PDF

17. Cabozantinib combination therapy for the treatment of solid tumors: a systematic review

Author

Castellano, D, Apolo, AB, Porta, C, Capdevila, J, Viteri, S, Rodriguez-Antona, C, Martin, L, and Maroto, P

Subjects
renal cell carcinoma, tyrosine kinase inhibitor, non-small-cell lung cancer, vascular endothelial growth factor, cabozantinib, solid tumor
Abstract

Background: Cabozantinib monotherapy is approved for the treatment of several types of solid tumors. Investigation into the use of cabozantinib combined with other therapies is increasing. To understand the evidence in this area, we performed a systematic review of cabozantinib combination therapy for the treatment of solid tumors in adults. Methods: This study was designed in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses, and the protocol was registered with PROSPERO (CRD42020144680). On 9 October 2020, we searched for clinical trials and observational studies of cabozantinib as part of a combination therapy for solid tumors using Embase, MEDLINE, and Cochrane databases, and by screening relevant congress abstracts. Eligible studies reported clinical or safety outcomes, or biomarker data. Randomized and observational studies with a sample size of fewer than 25 and studies of cabozantinib monotherapy were excluded. For each study, quality was assessed using National Institute for Health and Care Excellence methodology, and the study characteristics were described qualitatively. This study was funded by Ipsen. Results: Of 2421 citations identified, 32 articles were included (6 with results from randomized studies, 24 with results from non-randomized phase I or II studies, and 2 with results from both). The most commonly studied tumor types were metastatic urothelial carcinoma/genitourinary tumors and castration-resistant prostate cancer (CRPC). Findings from randomized studies suggested that cabozantinib combined with other therapies may lead to better progression-free survival than some current standards of care in renal cell carcinoma, CRPC, and non-small-cell lung cancer. The most common adverse events were hypertension, diarrhea, and fatigue. Conclusion: This review demonstrates the promising efficacy outcomes of cabozantinib combined with other therapies, and a safety profile similar to cabozantinib alone. However, the findings are limited by the fact that most of the identified studies were reported as congress abstracts only. More evidence from randomized trials is needed to explore cabozantinib as a combination therapy further.

Published
2022

18. P45.03 Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC as Identified by Liquid (LBx) or Tissue (TBx) biopsy

Author

Felip, E., primary, Garassino, M.C., additional, Sakai, H., additional, Le, X., additional, Veillon, R., additional, Smit, E., additional, Mazieres, J., additional, Cortot, A., additional, Raskin, J., additional, Thomas, M., additional, Viteri, S., additional, Iams, W., additional, Kim, H.R., additional, Yang, J., additional, Stroh, C., additional, Otto, G., additional, Bruns, R., additional, and Paik, P., additional

Published
2021
Full Text
View/download PDF

19. OA20.02 Pre-Treatment Levels of ctDNA for Long-Term Survival Prediction in Stage IIIA NSCLC Treated With Neoadjuvant Chemo-Immunotherapy

Author

Romero, A., primary, Nadal, E., additional, Serna, R., additional, Insa, A., additional, Campelo, M.R. García, additional, Benito, C., additional, Domine, M., additional, Majem, M., additional, Abreu, D. Rodriguez, additional, Martinez-Marti, A., additional, De Castro, J., additional, Cobo, M., additional, Vivanco, G. López, additional, Del Barco, E., additional, Bernabé, R., additional, Viñolas, N., additional, Barneto, I., additional, Viteri, S., additional, Pereira, E., additional, Royuela, A., additional, Casarrubios, M., additional, Calvo, V., additional, Laza - Briviesca, R., additional, Massuti, B., additional, Cruz, A., additional, Sánchez-Herrero, E., additional, and Provencio, M., additional

Published
2021
Full Text
View/download PDF

20. P68.05 Human Lung Carcinoma Primary Cultures From Malignant Pleural Effusions as a Tool for Drug Screening and Personalized Therapy

Author

Aguado Esteban, C., primary, García Peláez, B., additional, Cabrera, C., additional, Viteri, S., additional, Aguilar-Hernández, A., additional, Rodríguez, S., additional, Aldeguer, E., additional, Berrocal, L., additional, Roman, R., additional, Rubenstein, P., additional, Garcia-Casabal, F., additional, Mayo-De-Las-Casas, C., additional, Rosell, R., additional, and Molina-Vila, M.A., additional

Published
2021
Full Text
View/download PDF

21. P47.09 Tepotinib + Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2

Author

Dooms, C., primary, Nadal, E., additional, Raskin, J., additional, Demedts, I., additional, Mazieres, J., additional, Wislez, M., additional, Abdul, S., additional, Mun, T.L., additional, Wang, C., additional, Viteri, S., additional, Le, X., additional, How, S.H., additional, Tan, D., additional, Takeda, M., additional, Veillon, R., additional, Karachaliou, N., additional, Ellers-Lenz, B., additional, Smit, E., additional, and Wu, Y., additional

Published
2021
Full Text
View/download PDF

22. P22.04 Prospective Validation of an Eight Gene mRNA Signature in Plasma for the Diagnosis of Early Stage Lung Cancer

Author

Capitán, A. Giménez, primary, Rubinstein, P., additional, Rubinstein, F., additional, Aguilar-Hernández, A., additional, Bracht, J., additional, Viteri, S., additional, Cabrera-Gálvez, C., additional, Gonzalez-Cao, M., additional, Moya, I., additional, Valarezo, J., additional, Mayo-De-Las-Casas, C., additional, Pedraz, C., additional, Boykin, R., additional, Warren, S., additional, Rosell, R., additional, and Molina, M., additional

Published
2021
Full Text
View/download PDF

23. MA03.01 EPICAL Trial. A Phase Ib StudyCombining Anti-Epidermal Growth Factor (EGF) Vaccination With Afatinib in EGFR-Mutant Non-Small Cell Lung Cancer

Author

Abreu, D. Rodriguez, primary, Cobo, M., additional, Viteri, S., additional, Aguilar-Hernández, A., additional, Reguart, N., additional, Gonzalez-Cao, M., additional, Cabrera-Gálvez, C., additional, Moya, I., additional, Garcia-Roman, S., additional, Codony-Servat, J., additional, Peláez, B. García, additional, Ariza, N. Jordana, additional, Molina-Vila, M.A., additional, D'Hondt, E., additional, and Rosell, R., additional

Published
2021
Full Text
View/download PDF

26. OA20.01 Long Term Survival in Operable Stage Iiia Nsclc Patients Treated With Neoadjuvant Nivolumab Plus Chemotherapy - Nadim Study

Author

Provencio, M., primary, Nadal, E., additional, Insa, A., additional, Campelo, M.R. García, additional, Pereiro, D., additional, Domine, M., additional, Majem, M., additional, Abreu, D. Rodriguez, additional, Martinez-Marti, A., additional, De Castro, J., additional, Cobo, M., additional, Vivanco, G. López, additional, Del Barco, E., additional, Bernabé, R., additional, Viñolas, N., additional, Barneto, I., additional, Viteri, S., additional, Pereira, E., additional, Royuela, A., additional, Casarrubios, M., additional, Salas, C., additional, Parra, E.R., additional, Wistuba, I., additional, Calvo, V., additional, Laza - Briviesca, R., additional, Romero, A., additional, Massuti, B., additional, and Cruz, A., additional

Published
2021
Full Text
View/download PDF

27. P59.03 Comparison of Two RNA-Based Platforms for Detection of Fusions and Met Splicing Variant in Non Small Cell Lung Cancer Samples

Author

García Peláez, B., primary, Gimenez-Capitán, A., additional, Vives Usano, M., additional, Roman, R., additional, Garzón Ibañez, M., additional, Aguado Esteban, C., additional, Rodríguez, S., additional, Aldeguer, E., additional, Jordana Ariza, N., additional, Viteri, S., additional, Aguilar-Hernández, A., additional, Moya, I., additional, Cabrera, C., additional, Catalán, M., additional, Gonzalez-Cao, M., additional, García Román, S., additional, Bertrán- Alamillo, J., additional, Garcia-Casabal, F., additional, Rosell, R., additional, Molina, M., additional, and Mayo-De-Las-Casas, C., additional

Published
2021
Full Text
View/download PDF

28. 1196P Pre-existing and acquired mechanisms of resistance to lorlatinib in previously treated patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC)

Author

Solomon, B.J., primary, Martini, J-F., additional, Bearz, A., additional, Tan, E.H., additional, Soo, R., additional, Besse, B., additional, Bauer, T.M., additional, Shepard, D., additional, Toffalorio, F., additional, Abbattista, A., additional, Felip, E., additional, Shaw, A.T., additional, Viteri, S., additional, Camidge, D.R., additional, Seto, T., additional, and Ou, S-H.I., additional

Published
2021
Full Text
View/download PDF

29. LBA47 Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO): Final results of phase III Atalante-1 randomised trial

Author

Besse, B., primary, Garcia Campelo, M.R., additional, Cobo Dols, M.A., additional, Quoix, E., additional, Madroszyk, A., additional, Felip, E., additional, Cappuzzo, F., additional, Denis, F., additional, Hilgers, W., additional, Romano, G., additional, Debieuvre, D., additional, Baldini, E., additional, Galetta, D., additional, Viteri, S., additional, Phan, M., additional, Schuette, W., additional, Zer, A., additional, Costantini, D., additional, Dziadziuszko, R., additional, and Giaccone, G., additional

Published
2021
Full Text
View/download PDF

30. 1366TiP Tepotinib + osimertinib for EGFR-mutant NSCLC with resistance to first-line osimertinib due to MET amplification (METamp): INSIGHT 2

Author

Wu, Y-L., primary, Dooms, C., additional, Nadal, E., additional, Raskin, J., additional, Demedts, I., additional, Mazieres, J., additional, Wislez, M., additional, Shukor, S. Abdul, additional, Tho, L.M., additional, Wang, C-C., additional, Viteri, S., additional, Le, X., additional, How, S.H., additional, Tan, D., additional, Takeda, M., additional, Veillon, R., additional, Karachaliou, N., additional, Ellers-Lenz, B., additional, and Smit, E.F.F., additional

Published
2021
Full Text
View/download PDF

31. 1254P Efficacy and safety of tepotinib in patients (pts) with advanced age: VISION subgroup analysis of pts with MET exon 14 (METex14) skipping NSCLC

Author

Garassino, M.C.C., primary, Felip, E., additional, Sakai, H., additional, Le, X., additional, Veillon, R., additional, Smit, E.F.F., additional, Mazieres, J., additional, Cortot, A.B., additional, Raskin, J., additional, Thomas, M., additional, Viteri, S., additional, Iams, W.T., additional, Kim, H.R., additional, Yang, J., additional, Berghoff, K., additional, Bruns, R., additional, Otto, G., additional, and Paik, P.K., additional

Published
2021
Full Text
View/download PDF

32. 1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study

Author

Leighl, N.B., primary, Shu, C.A., additional, Minchom, A., additional, Felip, E., additional, Cousin, S., additional, Cho, B.C., additional, Park, K., additional, Han, J-Y., additional, Boyer, M., additional, Lee, C.K., additional, Garcia, V. Moreno, additional, Tomasini, P., additional, Viteri, S., additional, Xie, J., additional, Mertz, J., additional, Artis, E., additional, Schnepp, R.W., additional, Knoblauch, R.E., additional, Thayu, M., additional, and Perez, J.M. Trigo, additional

Published
2021
Full Text
View/download PDF

36. First-line osimertinib in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met

Author

Majem, M, Sullivan, I, Viteri, S, Lopez-Vivanco, G, Cobo, M, Sanchez, JM, Garcia-Gonzalez, J, Garde, J, Sampayo, M, Martrat, G, Malfettone, A, Karachaliou, N, Molina-Vila, MA, and Rosell, R

Subjects
EGFR Thr790Met mutation, NGS, Double mutations, NSCLC, Osimertinib
Abstract

Aim of the study: The AZENT (NCT02841579) study aimed to assess the efficacy and safety of first-line osimertinib in patients with epidermal growth factor receptor(EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC) and with a coexisting low allelic fraction of Thr790Met. Methods: In this multicentre, single-arm, open-label, phase IIa study, patients with locally advanced or metastatic NSCLC harbouring centrally confirmed EGFR Thr790Met mutation received 80 mg osimertinib daily. The primary end-point was objective response rate (ORR). The secondary end-points included disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and safety. Efficacy was assessed as per Response Evaluation Criteria in Solid Tumours, version 1.1. Blood samples collected at baseline, end of week 2 and disease progression were analysed using next-generation sequencing. As osimertinib was approved as a first-line therapy during the trial, this led to early termination of phase II; thus, analysis is considered exploratory. Results: Twenty-two patients were enrolled and received osimertinib. All 22 patients were included in the efficacy and safety analysis. At the data cutoff, 10 (50%) patients remained on treatment. The median duration of follow-up was 24.4 months (interquartile range 12.9 to 26.0). The ORR was 77.3% (17/22 [95% confidence interval {CI} 54.6 to 89.3]). The DCR was 86.4% (19/22, [95% CI 65.1 to 97.1]). The median PFS was 23.1 months (95% CI 14.1 to NE). The median OS was 28.4 months (95% CI 25.6 to NE). Conclusion: Despite early study termination, osimertinib first-line therapy yields an overall PFS of 23.1 months in EGFR-mutant patients harbouring a coexisting low allelic fraction of EGFR Thr790Met mutation. (C) 2021 Elsevier Ltd. All rights reserved.

Published
2021

37. Pre-treatment tissue TCR repertoire evenness is associated with complete pathological response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy

Author

Casarrubios M, Cruz-Bermudez A, Nadal E, Insa A, Garcia-Campelo R, Lazaro M, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, de Castro-Carpeno J, Cobo M, Lopez-Vivanco G, Del Barco E, Bernabe Caro R, Vinolas N, Barneto Aranda I, Viteri S, Massuti B, Barquin M, Laza-Briviesca R, Sierra-Rodero B, Parra E, Sanchez-Espiridion B, Rocha P, Kadara H, Wistuba I, Romero A, Calvo V, and Provencio M

Abstract

PURPOSE: Characterization of the T-cell receptor (TCR) repertoire may be a promising source for predictive biomarkers of pathological response to immunotherapy in locally-advanced non-small cell lung cancer (NSCLC). EXPERIMENTAL DESIGN: In this study, next-generation TCR sequencing was performed in peripheral blood and tissue samples of 40 NSCLC patients, before and after neoadjuvant chemoimmunotherapy (NADIM clinical trial, NCT03081689), considering their complete pathologic response (CPR) or non-CPR. Beyond TCR metrics, tissue clones were ranked by their frequency and spatiotemporal evolution of top 1% clones was determined. RESULTS: We have found a positive association between an uneven TCR repertoire in tissue samples at diagnosis and CPR at surgery. Moreover, TCR most frequent-ranked clones (top 1%) present in diagnostic biopsies occupied greater frequency in the total clonal space of CPR patients, achieving an AUC ROC to identify CPR patients of 0.967 (95% CI, 0.897 to 1.000; p=0.001), and improving the results of PD-L1 TPS (AUC 0.767; p=0.026) or TMB (AUC 0.550; p=0.687). Furthermore, tumors with high pre-treatment top 1% clonal space showed similar immune cell populations but a higher immune reactive gene expression profile. Finally, the selective expansion of pre-treatment tissue top 1% clones in peripheral blood of CPR patients suggests also a peripheral immunosurveillance, which could explain the high survival rate of these patients. CONCLUSIONS: We have identified two parameters derived from TCR repertoire analysis that could outperform PD-L1 TPS and TMB as predictive biomarkers of CPR after neoadjuvant chemoimmunotherapy, and unraveled possible mechanisms of CPR involving enhanced tumor immunogenicity and peripheral immunosurveillance.

Published
2021

42. 157P Tepotinib in patients (pts) with MET exon 14 (METex14) skipping NSCLC: Efficacy results from all pts enrolled in VISION cohort A

Author

Scherz, A., primary, Sakai, H., additional, Le, X., additional, Felip, E., additional, Veillon, R., additional, Garassino, M.C., additional, Raskin, J., additional, Viteri, S., additional, Mazieres, J., additional, Cortot, A., additional, Smit, E., additional, Thomas, M., additional, Conte, P., additional, Gottfried, M., additional, Britschgi, C., additional, Bruns, R., additional, Otto, G., additional, Johne, A., additional, and Paik, P., additional

Published
2021
Full Text
View/download PDF

43. 100MO Olaparib maintenance vs placebo in platinum-sensitive non-small cell lung cancer: The phase II randomized PIPSeN trial

Author

Postel-Vinay, S., primary, Planchard, D., additional, Antigny, M., additional, Sarto, J. Coves, additional, Gomez, M. Domine, additional, de las Penas Bataller, R., additional, Gonzalez, M.A. Sala, additional, Viteri, S., additional, Pérez, J. Pozas, additional, Texier, M., additional, Granados, A.L. Ortega, additional, Bueno, M.T. Moran, additional, Camps, C.J., additional, Lopez-Martin, A., additional, Provencio, M., additional, Gazzah, A., additional, Soria, J-C., additional, Besse, B., additional, Sureda, B. Massuti, additional, and Rosell, R., additional

Published
2021
Full Text
View/download PDF

44. P60.12 Baseline Tumor Immune Cell Infiltration and Activation can Predict Checkpoint Inhibitor Pneumonitis in Lung Cancer Patients

Author

Bracht, J., primary, Viteri, S., additional, Aguilar, A., additional, Garcia, J.J., additional, Huang, C., additional, Potie, N., additional, Aldeguer, E., additional, Giménez-Capitán, A., additional, Rodriguez, S., additional, Roman, R., additional, Warren, S., additional, Rosell, R., additional, Molina-Vila, M.A., additional, and González-Cao, M., additional

Published
2021
Full Text
View/download PDF

46. P84.01 The ARIA Study: Activity of Next-Generation ALK TKIs Based on ALK Resistance Mutations Detected by Liquid Biopsy in ALK Positive NSCLC Patients.

Author

Mezquita, L., primary, Swalduz, A., additional, Auclin, E., additional, Carter, M., additional, Steendam, C., additional, Aldea, M., additional, Scheffler, M., additional, Corral, J., additional, Viteri, S., additional, Segui, E., additional, Barba, A., additional, Dubbink, E., additional, Planchard, D., additional, Vasseur, D., additional, Reyes, R., additional, Caramella, C., additional, Recondo, G., additional, Saintigny, P., additional, Blackhall, F., additional, Dingemans, A., additional, and Besse, B., additional

Published
2021
Full Text
View/download PDF

48. FP14.15 Neratinib-Based Combination Therapy in HER2-Mutant Lung Adenocarcinomas: Findings from two International Phase 2 Studies

Author

Li, B., primary, Gandhi, L., additional, Besse, B., additional, Jhaveri, K., additional, Mazières, J., additional, Boni, V., additional, Shapiro, G., additional, Waqar, S., additional, Viteri, S., additional, Park, H., additional, Quinn, D., additional, Stemmer, S., additional, Cortot, A., additional, Burkard, M., additional, Scaltriti, M., additional, Won, H., additional, Lalani, A., additional, Mcculloch, L., additional, Bebchuk, J., additional, Xu, F., additional, Bryce, R., additional, Meric-Bernstam, F., additional, Piha-Paul, S., additional, Solit, D., additional, and Janne, P., additional

Published
2021
Full Text
View/download PDF

49. P60.07 TMB and Selected Mutations in Resectable Stage IIIA NSCLC Patients Receiving Neo-Adjuvant Chemo-Immunotherapy from NADIM Trial

Author

Cruz-Bermudez, A., primary, Casarrubios, M., additional, Briviesca, R. Laza, additional, Nadal, E., additional, Insa, A., additional, Mosquera, J., additional, Huidobro, G., additional, Gómez, M. Dómine, additional, Massuti, B., additional, Tarruella, M. Majem, additional, Rodríguez-Abreu, D., additional, Martinez-Marti, A., additional, De Castro Campeño, J., additional, Dols, M. Cobo, additional, Vivanco, G. López, additional, Del Barco, E., additional, Caro, R. Bernabé, additional, Viñolas, N., additional, Barneto, I., additional, Viteri, S., additional, Jove, M., additional, Romero, A., additional, Franco, F., additional, and Provencio, M., additional

Published
2021
Full Text
View/download PDF

50. OA04.04 Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer

Author

Sabari, J.K., primary, Shu, C.A., additional, Park, K., additional, Leighl, N., additional, Mitchell, P., additional, Kim, S., additional, Lee, J., additional, Kim, D., additional, Viteri, S., additional, Spira, A., additional, Han, J., additional, Trigo, J., additional, Lee, C.K., additional, Lee, K.H., additional, Girard, N., additional, Yang, T., additional, Goto, K., additional, Sanborn, R.E., additional, Yang, J.C., additional, Xie, J., additional, Roshak, A., additional, Thayu, M., additional, Knoblauch, R.E., additional, and Cho, B.C., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results